Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fadraciclib - Cyclacel Pharmaceuticals

Next Previous
Drug Profile

Fadraciclib - Cyclacel Pharmaceuticals

Alternative Names: CYC-065

Latest Information Update: 21 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Class Amines; Antineoplastics; Purines; Pyridines; Small molecules
  • Mechanism of Action Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Leukaemia; Lymphoma; Myelodysplastic syndromes; Solid tumours
  • Preclinical T-cell prolymphocytic leukaemia
  • No development reported Neuroblastoma

Most Recent Events

  • 06 Feb 2024 Cyclacel Pharmaceuticals suspends a phase I/II trials in Myelodysplastic syndromes (Monotherapy, Refractory metastatic disease, Second-line therapy or greater) and Leukaemia in USA (PO) due to slow enrollment and financial limitations (NCT05168904)
  • 18 Dec 2023 Efficacy and adverse events data from a Phase-I/II clinical trials in Solid tumours released by Cyclacel Pharmaceuticals
  • 09 Dec 2023 Preclinical trials in T-cell prolymphocytic leukaemia in USA (unspecified route), prior to December 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top